NCT07293065Active, not recruitingPhase 3
A Multicenter, Double-Blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Long-Term Protective Efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
MAXVAX Biotechnology Limited Liability Company4 sites in 1 country12,000 target enrollmentStarted: December 15, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 12,000
- Locations
- 4
- Primary Endpoint
- The person-year incidence of confirmed herpes zoster cases among individuals aged 40 years and older, 13 to 36 months after completing the full vaccination course with the investigational vaccine according to the 0- and 2-month immunization schedule.
Study Overview
Brief Summary
The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization schedule in individuals aged 40 years and older.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Participants in the MKKCT-100-003 study who have completed two doses of the investigational vaccine;
- •Males or females able to provide legal identity certificate;
- •Participants voluntarily agree to participate in the study, and sign the informed consent form;
- •Able to understand the study procedures and participate in all scheduled follow-up visits, and able to comply with the protocol requirements (such as cooperating in filling out questionnaires/scales, and being regularly contacted during the study for evaluation, etc.).
Exclusion Criteria
- •Participants who plan to use any products (drugs, vaccines, or medical devices) other than the investigational product for the prevention of VZV infection before signing the informed consent form or during the study period;
- •Participants with a history of herpes zoster;
- •Participants with any confirmed or suspected immunosuppressive or immunodeficiency condition caused by diseases (e.g., malignant tumors, human immunodeficiency virus infections, etc.) or immunosuppressive/cytotoxic treatments (e.g., medications used during cancer chemotherapy, organ transplantation, or treatment of autoimmune diseases);
- •Participants who are currently participating in or plan to participate in other clinical trials during the study;
- •Significant underlying diseases or any other condition that, in the opinion of the investigator, may prevent completion of the trial.
Arms & Interventions
Vaccine Group
Experimental
Subjects will receive Recombinant Zoster Vaccine (CHO cell) according to a 0, 2-month schedule
Intervention: Recombinant Zoster Vaccine (CHO Cell) (Biological)
Placebo Group
Placebo Comparator
Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
Intervention: NaCl solution Placebo (Biological)
Outcomes
Primary Outcomes
The person-year incidence of confirmed herpes zoster cases among individuals aged 40 years and older, 13 to 36 months after completing the full vaccination course with the investigational vaccine according to the 0- and 2-month immunization schedule.
Time Frame: At 13~36 months after the last vaccination
A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the Endpoint Adjudication Committee (EAC), consisting of physicians with HZ expertise.
Secondary Outcomes
- The person-year incidence of confirmed herpes zoster cases among individuals aged 40 years and older: from 30 days to 36 months after completing the full vaccination course, and the annual person-year incidence from 30 days after the full vaccination.(At 30 days~36 months after the last vaccination.)
- The person-year incidence rate of confirmed Herpes Zoster (HZ) cases during the periods of 30 days to 36 months, 13 to 36 months, and annually after 30 days post full-course immunization, in populations of different age groups.(30 days to 36 months, 13 to 36 months, and 30 days after the last vaccination.)
- Incidence of any and severe Postherpetic Neuralgia (PHN) cases per person years in subjects aged 40 years and older, 40-49years , 50-59 years , 60-69 years and ≥70 years , with confirmed HZ.(30 days after the last vaccination.)
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Recruiting
Phase 3
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)NCT07272434MAXVAX Biotechnology Limited Liability Company25,000
Recruiting
Phase 3
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster VaccineVaccine-Preventable DiseasesHerpes ZosterNCT06088745Beijing Luzhu Biotechnology Co., Ltd.4
Recruiting
Phase 1
A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster VaccineVaccine-Preventable DiseasesHerpes ZosterNCT05750017Beijing Luzhu Biotechnology Co., Ltd.66
Completed
Phase 2
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)Inflammatory ArthritisArthritisPsoriasisCrohn's DiseasePsoriatic ArthritisRheumatoid ArthritisAnkylosing SpondylitisEnteropathic ArthritisNCT02538341University of Alabama at Birmingham617
Unknown
Phase 4
Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic PatientsHerpes ZosterNCT03016884HaEmek Medical Center, Israel87